English
Вакцинация как ключевой элемент борьбы с эпидемией и пандемией
DOI: https://dx.doi.org/10.18565/therapy.2023.2.48-54
А.М. Осадчук, И.Д. Лоранская, М.А. Осадчук
1) ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, г. Москва; 2) ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)
Литература
1. Plotkin S. History of vaccination. Proc Natl Acad Sci USA. 2014; 111(34): 12283–87. https://dx.doi.org/10.1073/pnas.1400472111. 2. Gualano M.R., Olivero E., Voglino G. et al. Knowledge, attitudes and beliefs towards compulsory vaccination: A systematic review. Hum Vaccin Immunother. 2019; 15(4): 918–31. https://dx.doi.org/10.1080/21645515.2018.1564437. 3. Excler J.-L., Saville M., Berkley S., Kim J.H. Vaccine development for emerging infectious diseases. Nat Med. 2021; 27(4): 591–600. https://dx.doi.org/10.1038/s41591-021-01301-0. 4. Renosa M.D.C., Landicho J., Wachinger J. et al. Nudging toward vaccination: a systematic review. BMJ Glob Health. 2021; 6(9): e006237. https://dx.doi.org/10.1136/bmjgh-2021-006237. 5. Li X., Mukandavire C., Cucunuba Z.M. et al. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: A modelling study. Lancet. 2021; 397(10272): 398–408.https://dx.doi.org/10.1016/S0140-6736(20)32657-X. 6. Barrett S., Hoel M. Optimal disease eradication. Environ Dev Econ. 2007; 12(5): 627–52. https://dx.doi.org/10.1017/S1355770X07003816. 7. Autran B., Launay O., Floret D. Vaccinations. EMC – Maladies infectieuses. 2016; Article 8-002-Q-10: 1-14.https://dx.doi.org/10.1016/S1166-8598(15)49465-7. 8. Canoui E., Launay O. Histoire et principes de la vaccination. Rev Mal Respir. 2019; 36(1): 74–81. 9. Zepp F. Principles of vaccination. Methods Mol Biol. 2016; 1403: 57–84. https://dx.doi.org/10.1007/978-1-4939-3387-7_3. 10. Gasper D.J., Tejera M.M., Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol. 2014; 34(2): 121–46.https://dx.doi.org/10.1615/critrevimmunol.2014010373. 11. Eibel H., Kraus H., Sic H. et al. B cell biology: An overview. Curr Allergy Asthma Rep. 2014; 14(5): 434.https://dx.doi.org/10.1007/s11882-014-0434-8. 12. Merle N.S., Noe R., Halbwachs-Mecarelli L. et al. Complement system part II: Role in immunity. Front Immunol. 2015; 6: 257.https://dx.doi.org/10.3389/fimmu.2015.00257. 13. Trofin F., Nastase E.V., Iancu L.S. et al. Anti-RBD IgA and IgG response and transmission in breast milk of anti-SARS-CoV-2 vaccinated mothers. Pathogens. 2022; 11(3): 286. https://dx.doi.org/10.3390/pathogens11030286. 14. Pollard A.J., Bijker E.M. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021; 21(2): 83–100. https://dx.doi.org/1038/s41577-020-00479-7. 15. Timing and spacing of immunobiologics. General best practice guidelines for immunization: Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Updated September 8, 2022. CDC. Accessed, October, 21, 2022.URL: https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/timing.html (date of access – 01.03.2023). 16. Dai X., Xiong Y., Li N., Jian C. Vaccine types. March 5th, 2019. https://dx.doi.org/10.5772/intechopen.84626. Accessed, October, 21, 2022. URL: https://www.intechopen.com/chapters/65813 (date of access – 01.03.2023). 17. Jaurigue J.A., Seeberger P.H. Parasite carbohydrate vaccines. Front Cell Infect Microbiology. 2017; 7: 248.https://dx.doi.org/10.3389/fcimb.2017.00248. 18. Pulendran B.S., Arunachalam P., O’Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov. 2021; 20(6): 454–75. https://dx.doi.org/10.1038/s41573-021-00163-y. 19. Xia S., Zhang Y., Wang Y. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020; 21(1): 39–51. https://dx.doi.org/10.1016/S1473-3099(20)30831-8. 20. Zhang Y., Zeng G., Pan H. et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21(2): 181–92.https://dx.doi.org/10.1016/ S1473-3099(20)30843-4. 21. Djurisic S., Jakobsen J.C., Petersen S.B. et al. Aluminium adjuvants used in vaccines. Cochrane Database Syst Rev. 2018; (7): CD013086. https://dx.doi.org/10.1002/14651858.CD013086. 22. Gilsdorf J.R. Hib vaccines: Their impact on Haemophilus influenzae type b disease. J Infect Dis. 2021; 224(12 Suppl 2): S321–S330. https://dx.doi.org/10.1093/infdis/jiaa537. 23. Desai A.N., Majumder M.S. What is herd immunity? JAMA. 2020; 324(20): 2113. https://dx.doi.org/10.1001/jama.2020.20895. 24. Bolotin S., Wilson S., Murti M. Achieving and sustaining herd immunity to SARS-CoV-2. CMAJ. 2021; 193(28): E1089.https://dx.doi.org/10.1503/cmaj.210892. 25. Vaccine-preventable diseases. European Centre for Disease Prevention and Control. Accessed, October, 21, 2022.URL: https://www.ecdc.europa.eu/en/vaccine-preventable-diseases (date of access – 01.03.2023). 26. Bloom D.E., Cadarette D. Infectious disease threats in the twenty-first century: Strengthening the global response. Front Immunol. 2019; 10: 549. https://dx.doi.org/10.3389/fimmu.2019.00549. 27. Hatchett R. Prepare to prevent: Developing pandemic-busting vaccines against «Disease X». United Nations. UN Chronicle. 27 December 2021. Accessed, October, 21, 2022. URL: https://www.un.org/en/un-chronicle/prepare-prevent-developing-pandemic-busting-vaccines-against-%E2%80%9Cdisease-x%E2%80%9D (date of access – 01.03.2023). 28. WHO. 2018 annual review of diseases prioritized under the research and development blueprint. 6–7 February 2018. Geneva, Switzerland. Accessed, October, 21, 2022. URL: https://www.who.int/news-room/events/detail/2018/02/06/default-calendar/2018-annual-review-of-diseases-prioritized-under-the-research-anddevelopment-blueprint (date of access – 01.03.2023). 29. WHO. Pandemic influenza preparedness framework: For the Sharing of influenza viruses and access to vaccines and other benefits. 2011. Accessed, October, 21, 2022. URL: https://apps.who.int/iris/bitstream/handle/10665/44796/9789241503082_eng.pdf (date of access – 01.03.2023). 30. Shrestha Y., Shivalingegowda R.K., Avinash M.J. et al. The rise in antimicrobial resistance: An obscure issue in COVID-19 treatment. PLOS Glob Public Health. 2022; 2(7): e0000641. https://dx.doi.org/10.1371/journal.pgph.0000641.
Об авторах / Для корреспонденции
Алексей Михайлович Осадчук, д.м.н., профессор, профессор кафедры гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 121552, г. Москва, ул. академика Павлова, д. 22. E-mail: a.m.osadchuk@2020mail.ru.
ORCID: https://orcid.org/0000-0002-8488-9235. Scopus ID: 24576966600
Ирина Дмитриевна Лоранская, д.м.н., профессор, зав. кафедрой гастроэнтерологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России. Адрес: 121552, г. Москва, ул. академика Павлова, д. 22. E-mail: gastromapo@yandex.ru.
ORCID: https://orcid.org/0000-0002-3681-4132. Scopus ID 36164230100
Михаил Алексеевич Осадчук, д.м.н., профессор, зав. кафедрой поликлинической терапии ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет). Адрес: 119333, г. Москва, ул. Фотиевой, д. 10. E-mail: osadchuk.mikhail@yandex. ru. ORCID: https://orcid.org/0000-0003-0485-6802. eLibrary SPIN: 3108-0478; Scopus ID: 6701741609
Похожие статьи
